
Nextcure (NXTC) Stock Forecast & Price Target
Nextcure (NXTC) Analyst Ratings
Bulls say
NextCure Inc. is poised for growth due to its promising product candidates, particularly LNCB74, which has shown superior efficacy in preclinical models compared to competitor constructs, suggesting a strong potential advantage in treating various cancers, including endometrial cancer. The preclinical results for NC181 indicate that it effectively targets ApoE4, showing robust efficacy in amyloid clearance and neuroinflammation, which is significant as it addresses Alzheimer’s disease, a major unmet medical need. Furthermore, the company's ongoing enrollment in clinical cohorts signals confidence in safety and effective development processes, enhancing its market positioning amidst a competitive landscape.
Bears say
NextCure Inc. is facing a negative outlook due to the discontinuation of Pfizer's B7-H4 ADC program, which raises concerns about the viability of B7-H4 targeted therapies like LNCB74. Additionally, the company's operating expenses in the fourth quarter of 2024 exceeded previous expectations, contributing to a revised price target. These factors reflect potential operational and market challenges that may hinder the company's growth and financial performance.
This aggregate rating is based on analysts' research of Nextcure and is not a guaranteed prediction by Public.com or investment advice.
Nextcure (NXTC) Analyst Forecast & Price Prediction
Start investing in Nextcure (NXTC)
Order type
Buy in
Order amount
Est. shares
0 shares